Join Costello Medical at ISPOR 2026 in Philadelphia, US in May, where we will come together with other global healthcare leaders, researchers and decision makers to explore the theme of “HEOR at the Forefront of Policy, Access, and Value.”
Discover information on our attendees, details of our booth in the conference exhibition hall and a summary of research we are proud to have contributed to the conference. Return to this page after the conference to access our insights on the key topics discussed.
We will be located at Booth 440 within the main exhibition hall, where you’ll always be able to find someone from Costello Medical and learn more about our company and services. We look forward to meeting with you! If you would like to book a meeting with us ahead of time, please feel free to reach out to any of our attendees listed below.
We’re delighted to have a team of 13 people attending the conference, including experts in our evidence development (literature reviews, statistics and real-world evidence) and value & access (market access, HTA and health economics) services, as well as representatives from our dedicated MedTech and rare diseases teams.
Value & Access
Evidence Development
Expertise in MedTech and Rare Diseases
We have a number of key focuses for the conference, including Joint Clinical Assessment (JCA), the recent expansion of our Canadian HEOR and Access Services and the potential for technical innovation and artificial intelligence (AI) to facilitate advances in HEOR.
The potential for technical innovation and AI to facilitate advances in HEOR remains an important priority for us.
Our research at ISPOR 2026 explores the use of AI in evidence synthesis, reflecting our commitment to advancement in this area.
At Costello Medical, our approach is continually evolving, and our scientific teams collaborate with our dedicated Innovation and Engineering teams to identify and act on possibilities for innovation. Currently in development, our literature review platform incorporates AI-assisted screening and data extraction.
We also advise on where digital technologies can add genuine value and enhance your project, from incorporating AI for efficiency gains, to pioneering new approaches to create bespoke deliverables that best meet your needs. Find further details of our approach, services, AI principles and examples of our latest work on our Technical Innovation and AI page.
If you have any questions about how AI could be used to support your objectives, or would be interested in collaborating with us, please reach out to Natalie Hearmon or any of our conference attendees.
The JCA process is now well underway in Europe, with industry preparing for its expansion over the coming years. We offer a comprehensive range of JCA services to ensure JCA readiness and high-quality JCA dossier delivery.
We look forward to discussing our experience across JCA and JSC projects to date at ISPOR. This includes full end-to-end support for one of the first products to undergo JSC in 2025, alongside extensive experience in PICO simulation, JCA evidence planning and, more recently, JCA submission dossier writing. We also support Global teams in navigating HTA strategy across both EU JCA and ex-EU markets, ensuring aligned and efficient evidence generation and planning.
Our ongoing series of deep-dive webinars on JSC and JCA share practical lessons and recommendations from our early experience of PICO simulation, the JSC process, and working with rare disease biotechs. Join our mailing list to be the first to hear about our upcoming webinars.
Please reach out to Grace Lambert or any of our other conference attendees to discuss how we can support your EU HTA needs.
We recently opened a Vancouver office to support clients in Canada across our full range of services in Evidence Development, Value & Access, and Medical Communications.
Our team provides tailored support across Canadian HTA strategy, scientific advice, SLRs and ITCs, Canadian-specific RWE, economic modelling, and HTA dossier development for CDA-AMC, INESSS, and private payers. Explore the full details of our Value & Access and Evidence Development services, now delivered locally in Canada.
Our work is complemented by a network of Canadian experts, including former payers and technical specialists.
We also support Global teams in aligning Canadian HTA with wider market access strategy, ensuring efficient and coherent evidence generation across Canada and ex-Canada markets.
Please reach out to Rose Wickstead or any of our other conference attendees to discuss how we can support your Canadian HTA needs.
We are delighted to be delivering a podium presentation at ISPOR 2026. Explore the session details and timings.
We are thrilled to present 4 research posters at ISPOR 2026. Discover the titles of our research, alongside the poster session dates and times.
Monday,
18 May
Tuesday,
19 May
Tuesday,
19 May
Following the conference, our attendees will prepare commentaries on a variety of specific topics from ISPOR 2026. Watch this space for the link to our commentaries soon after the conference!
